Press Releases

 
Press Releases
  Date Title and Summary View
Dec 15, 2014
HAYWARD, Calif., Dec. 15, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced today that Anthera and Zenyaku Kogyo Co., Ltd. of Tokyo, Japan executed an exclusive license agreement for the development and commercialization of subcutaneous blisibimod in Japan and potentially other countries throughout Asia.  Anthera retains f...
Nov 23, 2014
HAYWARD, Calif., Nov. 23, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update at the 2014 Annual Piper Jaffray Healthcare Conference. Anthera will present at 4:30PM ET, December 3rd, at the Palace Hotel in New York City....
Nov 20, 2014
HAYWARD, Calif., Nov. 20, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) announced today it has signed a manufacturing and supply agreement with the Patheon® division of DPx Holdings B.V.  The contract provides for Patheon to support the production of the Sollpura® clinical drug product for Anthera's Phase III registrat...
Nov 14, 2014
HAYWARD, Calif., Nov. 14, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the third quarter ended September 30, 2014. Net loss for the three months ended September 30, 2014 was $7.0 million, compared to $5.8 million for the same period in 2013. The increase in n...
Oct 1, 2014
HAYWARD, Calif., Oct. 1, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States. Anthera does not intend to communicate further regarding these discussions unless and until ...
Jul 28, 2014
HAYWARD, Calif., July 28, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014. Net loss for the three months ended June 30, 2014 was $7.3 million, compared to $8.3 million for the same period in 2013. The decrease in net loss i...
Jul 14, 2014
HAYWARD, Calif., July 14, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy ("PERT") from Eli Lilly and Company.  Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patien...
Jun 23, 2014
HAYWARD, Calif., June 23, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Brian R. Mueller to its Board of Directors and as Chairman of the Audit Committee of the Board of Directors.  Mr. ...
Jun 13, 2014
HAYWARD, Calif., June 13, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Dr. Philip Sager, MD, FACC, FAHA, FHRS, to its Board of Directors. Dr. Sager is a Fellow of the American ...
May 13, 2014
HAYWARD, Calif., May 13, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the first quarter ended March 31, 2014. First Quarter 2014 Financial Results: Net loss for the first quarter ended March 31, 2014 was $7.9 million, compared to $7.6 million for the ...
Page:
1
... NextLast
= add release to Briefcase
JoomShaper